The global single-use bioreactor market was valued at USD 3.2 billion in 2020 and is anticipated to reach USD 9.1 billion by 2027, registering a CAGR of 21.1% during the forecast period 2021-2027.

Factors attributing to the growth of global single-use bioreactor market owing to the criticality of the step, fully automated technology, and time is taken for product development and production. In addition, robust adoption of disposable technology in the pharmaceutical and biotech industry, cost-effectiveness and less downtime of the single-use bioreactor, initiatives by the government to support biopharma research, the rising trend in biopharmaceuticals, and product launch will lead to the growth of 21.1% CAGR in the single-use bioreactor market.

The potential opportunities in developing economies, rising demand for personalized medicine, and mounting adoption of biosimilar products in the US will propel the growth of the single-use bioreactor market. Single-use bioreactors are growing significantly in the healthcare sector and are increasingly adopted by pharmaceutical companies to produce drugs without negotiating the quality. Moreover, single-use bioreactors are flexible as they can produce different drugs in the same facility at minimum time and at less cost.

Request to get a free sample copy at https://www.vynzresearch.com/healthcare/single-use-bioreactor-market/request-sample

Based on product, the single-use bioreactor system is anticipated to hold a significant share as these are increasingly used in biopharmaceutical processes as it offers flexibility, less investment, less environmental footprint, and limited operational cost. They are increasingly adopted in drug discovery, pharmaceutical, and life science, development of vaccines, antibodies, cell structure.

Based on the type of molecule, the monoclonal antibodies dominates the market in 2020 owing to the rising demand for SUBs in the production of mAbs, less investment, less requirement of the workforce, and reduced time-consuming changeover procedures.

North America dominates the market owing to the well-established biopharmaceutical industry and the presence of industry players operating single-use bioreactors in the region. The rising prominence of molecular biology and DNA sequencing will drive the growth of the single-use bioreactor system market in the region.

Sartorius Stedim Biotech has launched with BIOBRAIN, a BIOSTAT STR Generation 3 so as to make biopharmaceutical development and production faster, easier, and safer.
The prominent players in the single-use bioreactor system industry include Sartorius Stedim Biotech, Eppendorf, Merck Millipore, Cesco Bioengineering, GE Healthcare, Applikon Biotechnology, Danaher, Thermo Fisher Scientific, Parker Hannifin, Cellexus, and Celltainer Biotech.

Source: VynZ Research